Fibromyalgia Pain & Function Protocol
The best supported part of Nancy Klimas's fibromyalgia approach is energy-envelope pacing with structured symptom tracking, and that is what this protocol leads with. Low-dose naltrexone (LDN) is covered honestly as an option some physicians use off-label: the early small trials looked promising, and every larger randomized trial since has failed to beat placebo. No dosing is given here, and nothing on this page is a treatment plan.
Pace to your energy envelope: stay under your activity ceiling and stop before exhaustion Every day, on good days as well as bad ones. The same threshold-based method Klimas and exercise physiologist Connie Sol use in their ME/CFS work
Overexerting on a good day is what drives the boom and bust crash cycle. Holding activity steady is what limits flares, and it is the highest-value thing on this page.
Track pain weekly on a 0-10 scale One rating a week, ideally the same day and time, alongside a note on how much activity that week held
Fibromyalgia fluctuates on its own, so a single good or bad week tells you nothing. A weekly number over a couple of months is what lets you and your physician separate a real change from normal variation, whatever you are trying.
Give sleep its own physician-guided plan rather than expecting a pain treatment to fix it Discussed with a physician familiar with fibromyalgia, since some fast-acting sedatives can worsen non-restorative sleep
Even the trials that found a pain signal for LDN did not reliably show improvement in sleep or fatigue. Sleep is its own problem and needs its own plan.
Ask your physician about screening for thyroid disease (TSH, free T4), iron deficiency (a complete blood count and iron studies), and joint hypermobility (can you bend your thumb back to your forearm, or your elbows and knees past straight); ask about a sleep study if you snore or wake unrefreshed Once as a baseline, then thyroid and iron rechecked on your physician's schedule
Hypermobility, including hypermobile Ehlers-Danlos syndrome, overlaps with fibromyalgia far more than chance would predict in observational studies, one clinic sample found more than half of hypermobility-spectrum patients also met fibromyalgia criteria. Thyroid disease, iron deficiency and sleep apnea are common, treatable, and easy to miss when every symptom gets attributed to fibromyalgia alone. None of this replaces a fibromyalgia treatment plan; it is what to rule out alongside it.
If you take opioid painkillers, or might need them, tell your doctor before any naltrexone conversation Informational only. This is a conversation to have with your prescriber, not a step to act on yourself
Naltrexone is an opioid antagonist. It blocks opioid painkillers and can precipitate acute withdrawal in someone who is opioid-dependent. Every fibromyalgia trial excluded opioid users, so there is no randomized evidence in people taking them, and they are a large share of chronic-pain patients. The antagonist effect also persists for roughly two to three days after the last dose, which matters for surgery and emergency pain relief.
Treat low-dose naltrexone as an unproven option to discuss, not a step to take No dosing is given on this page. Every low dose of naltrexone is compounded, since there is no FDA-approved low-dose product, and the decision belongs entirely to a prescribing physician
Klimas's clinical use of LDN is real and reported, and clinical practice is not the same thing as trial evidence. The larger randomized trials have not beaten placebo, and no guideline recommends it. It is generally well tolerated in trials, with vivid dreams the most consistent side effect, so the honest framing is low expected benefit rather than high risk.
Be skeptical of clinics selling high-dose IV vitamin infusions ('Myers cocktails'), stem-cell or exosome injections, long-term antibiotic courses marketed as a 'chronic Lyme' cure, or rife/bioresonance frequency devices for fibromyalgia N/A, this is what to avoid, not what to do
None of these has trial evidence showing benefit for fibromyalgia. The FDA has stated plainly that no stem-cell or exosome product is approved to treat chronic pain or fatigue. The CDC documents that prolonged antibiotic or IV therapy for 'chronic Lyme' lacks proven benefit and has caused real harm, including septic shock and C. difficile infection. Frequency/energy devices marketed with cure claims have drawn FDA enforcement action for similar claims in other diseases; none is FDA-approved to treat fibromyalgia. This page already shows you what happened when a real treatment (LDN) was tested properly: it is worth remembering that a good story from a clinic is not the same thing as a trial result.
Reassess with your physician on a set schedule and agree in advance what would count as working Regular check-ins, with your weekly tracking in hand
Deciding upfront what a real response looks like, and by when, is what stops an unproven treatment continuing indefinitely on hope. Any off-label medication is monitored and adjusted by the prescriber, never independently.
Pacing is the well supported part of this protocol, and low-dose naltrexone is the part the larger evidence has turned against.
View sources
Ep 35: Finding Treatments for Fibromyalgia and ME/CFS
Finding Treatments for Fibromyalgia and ME/CFS
General Klimas / INIM clip (not fibromyalgia-specific)
Institute for Neuro-Immune Medicine (Nova Southeastern University)
FDA-approved fibromyalgia medications: pregabalin, duloxetine, milnacipran
CDC, Monitoring the Use of Medicines and Supplements (ME/CFS)
CDC, Chronic Symptoms and Lyme Disease: risks of prolonged antibiotic therapy
FDA, Products Claiming to 'Cure' Cancer Are a Cruel Deception (general FDA stance on unapproved cure-claim devices)
Low-dose naltrexone for the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, counterbalanced crossover trial (Younger, Noor, McCue & Mackey, Arthritis and Rheumatism, 2013)
Low-dose naltrexone for treatment of pain in patients with fibromyalgia: a randomized, double-blind, placebo-controlled, crossover study (Bested et al., Pain Reports, 2023)
Efficacy and safety of low-dose naltrexone for fibromyalgia (FINAL): a randomised, double-blind, placebo-controlled trial (Lancet Rheumatology, 2024)
Low-dose naltrexone in fibromyalgia: a 12-month randomised, double-blind, placebo-controlled trial (INNOVA, European Journal of Pain, 2026)
Efficacy of low-dose naltrexone in chronic pain: a systematic review and meta-analysis (Hegde et al., Current Pain and Headache Reports, 2025)
Amitriptyline for fibromyalgia in adults (Moore et al., Cochrane Database of Systematic Reviews, 2015)
Raj et al., Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome
Eccles et al., Beyond bones: the relevance of variants of connective tissue (hypermobility) to fibromyalgia, ME/CFS and controversies surrounding diagnostic classification
High overlap in patients diagnosed with hypermobile Ehlers-Danlos syndrome or hypermobile spectrum disorders with fibromyalgia and 40 self-reported symptoms and comorbidities
Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Independent curation. YourProtocol is an independent platform. This protocol is based on the publicly available work of Nancy Klimas and is not created, reviewed, endorsed by, or affiliated with Nancy Klimas or MD, Director, Institute for Neuro-Immune Medicine · Nova Southeastern University.
Is this for you
- People diagnosed with fibromyalgia who want a pacing and tracking method they can start on their own, alongside their physician's care
- Anyone who has read about low-dose naltrexone online and wants the honest evidence picture, including what the larger trials found
- Caregivers helping someone manage activity limits and flares
- Not a self-prescribing guide, and not a substitute for diagnosis and ongoing care from a physician
Cautions
- Naltrexone is an opioid antagonist. It blocks opioid painkillers and can precipitate acute withdrawal in anyone who is opioid-dependent, and the effect persists for roughly two to three days after the last dose, which matters for surgery and emergency pain relief. Every fibromyalgia trial excluded opioid users, so there is no randomized evidence in people taking them. Tell every clinician you see.
- Low-dose naltrexone is prescription-only and off-label for fibromyalgia. There is no FDA-approved product at any low dose, so every low dose is compounded, and the FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.
- The larger randomized trials of low-dose naltrexone in fibromyalgia have not beaten placebo, and no major guideline recommends it. Treat it as unproven, not as an established treatment.
- Never self-prescribe or source naltrexone. Tell your doctor about every medication and supplement you take.
- Fibromyalgia requires diagnosis and ongoing care from a physician. This page is pacing and tracking support, not a treatment plan on its own.
- Educational only, not medical advice.
Common questions
Some links earn us a commission. It never affects our picks or grades. See our affiliate disclosure.